A 24 week Double-blind, Placebo-controlled Study using Terazosin in Treatment of Benign Prostatic Hyperplasia.
- Author:
Jun Seong JEON
1
;
Jae Mann SONG
Author Information
1. Department of Urology, Wonju College of Medicine, Yonsei, University.
- Publication Type:Original Article
- Keywords:
Benign prostatic hyperplasia;
Terazosin
- MeSH:
Follow-Up Studies;
Humans;
Prostatic Hyperplasia*
- From:Korean Journal of Urology
1994;35(7):755-759
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The double-blind, placebo-controlled study was performed to evaluate the efficacy and safety of once-a-day terazosin in 35 patients with benign prostatic hyperplasia. The dose of terazosin was titrated to 5 mg during 4 week period and then maintained throughout 24 week follow up. In terazosin group(n= 18), the maximum flow rates improved 32% from 10.4ml/sec at baseline to 13.7ml/sec, and the mean flow rate improved 38% from 5.5ml/sec to. 7.6ml/sec after 24 weeks of treatment(p <0.01). The obstructive symptom score decreased 59% from 9.8 to 4.l, and the irritative symptom score decreased 34% from 5.4 to 3.5 after.24 weeks of terazosin therapy (p<0.01). In placebo group(n= 17), the obstructive symptom score only significantly decreased 39% from 9.1 at baseline to 5.5 after 24 weeks of terazosin therapy(p>0.06). Adverse event occurred in one case of the terazosin group. In summary, terazosin administered once-a-day improved the obstructive and irritative symptoms of BPH and urine flow rates. Terazosin was well tolerated.
